2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME
C. Dean Buckner, MD

ASCO 2007: Targeted Therapy and Renal Cell Carcinoma: Are We Making Progress?
Robert J. Amato, DO, Weill Medical College of Cornell University, University of Texas Health Science Center - Houston, The Methodist Hospital Research Institute, Houston, Texas

ASCO 2007: Update on the Management of Genitourinary Malignancies
Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center

Current Topics

Excess Body Weight Linked with More Than 100,000 New Cancer Diagnoses Each Year in U.S. (11/12/2009)
According to estimates from the American Institute for Cancer Research (AICR), excess body weight may be responsible for more than 100,000 new cancer diagnoses each year in the United States.

Low-dose Interferon-alfa Does Not Improve Outcomes of Patients with Renal Cell Carcinoma Receiving Nexavar® (11/4/2009)
Researchers from the M. D. Anderson Cancer Center have reported that the addition of low-dose interferon-alfa (IFN) to Nexavar® (sorafenib) did not improve survivals of patients with advanced renal cell carcinoma (RCC). The details of this study were published early online in Cancer on October 27. 2009.

Nexavar® May Reduce Brain Metastases in Patients with Metastatic Renal Cell Carcinoma (10/28/2009)
Researchers from France and Poland have reported that Nexavar® (sorafenib) may reduce the incidence of brain metastases in patients with metastatic renal cell carcinoma (RCC). The details of this study appeared early online on October 22, 2009 in the Annals of Oncology.

Oral Targeted Agent Recentin™ Active in Renal Cell Carcinoma (9/25/2009)
Researchers involved in an international randomized Phase II clinical trial have reported that Recentin™ (cediranib), a potent inhibitor of vascular endothelial growth factor (VEGF) tyrosine kinases, is active for the treatment of patients with advanced renal cell carcinoma (RCC). The details of this study were presented as a late-breaking abstract at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.

Oral Tyrosine Multi-kinase Inhibitor, Pazopanib, Active in Advanced Renal Cell Carcinoma (9/24/2009)
Researchers from Europe have reported that pazopanib is an active new tyrosine kinase inhibitor for treating renal cell carcinoma. The details of this study were presented at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.